Viability of Long-Term Gene Therapy in the Cochlea
AuthorAtkinson, PJ; Wise, AK; Flynn, BO; Nayagam, BA; Richardson, RT
Source TitleSCIENTIFIC REPORTS
PublisherNATURE PUBLISHING GROUP
University of Melbourne Author/sWise, Andrew; Nayagam, Bryony; Richardson, Rachael; ATKINSON, PATRICK; FLYNN, BRIANNA
Audiology and Speech Pathology
Medical Bionics Department
Document TypeJournal Article
CitationsAtkinson, PJ; Wise, AK; Flynn, BO; Nayagam, BA; Richardson, RT, Viability of Long-Term Gene Therapy in the Cochlea, SCIENTIFIC REPORTS, 2014, 4
Access StatusOpen Access
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994438
NHMRC Grant codeNHMRC/1064375
Gene therapy has been investigated as a way to introduce a variety of genes to treat neurological disorders. An important clinical consideration is its long-term effectiveness. This research aims to study the long-term expression and effectiveness of gene therapy in promoting spiral ganglion neuron survival after deafness. Adenoviral vectors modified to express brain derived neurotrophic factor or neurotrophin-3 were unilaterally injected into the guinea pig cochlea one week post ototoxic deafening. After six months, persistence of gene expression and significantly greater neuronal survival in neurotrophin-treated cochleae compared to the contralateral cochleae were observed. The long-term gene expression observed indicates that gene therapy is potentially viable; however the degeneration of the transduced cells as a result of the original ototoxic insult may limit clinical effectiveness. With further research aimed at transducing stable cochlear cells, gene therapy may be an efficacious way to introduce neurotrophins to promote neuronal survival after hearing loss.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References